SAB Biotherapeutics Stock (NASDAQ:SABS)

Forecast Ownership Financials Chart

Previous Close

$3.42

52W Range

$1.85 - $5.15

50D Avg

$3.70

200D Avg

$3.81

Market Cap

$310.26M

Avg Vol (3M)

$666.87K

Beta

0.54

Div Yield

SABS Company Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Feb 09, 2021

Website

SABS Performance

SABS Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	$1.32M	$2.24M
Operating Income	$-48.95M	$-42.91M	$-38.08M
Net Income	$13.27M	$-34.11M	$-42.19M
EBITDA	$-48.95M	$-28.99M	$-38.13M
Basic EPS	$0.22	$-3.68	$-7.64
Diluted EPS	$-0.79	$-3.68	$-7.64

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
PLUR	Pluri Inc.
NXTC	NextCure, Inc.
QTTB	Q32 Bio Inc.
JSPR	Jasper Therapeutics, Inc.
ANTX	AN2 Therapeutics, Inc.
EVAX	Evaxion Biotech A/S
VRCA	Verrica Pharmaceuticals Inc.
BOLD	Boundless Bio, Inc.
GBIO	Generation Bio Co.